Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Cohen

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Annals of the Rheumatic Diseases|June 7, 2017
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence studyStanley Cohen, Mark C Genovese, Ernest Choy, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|April 7, 2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyJürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, et al.
RMD Open|April 19, 2019
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54Rieke Alten, Bogdan Batko, Tomas Hala, et al.
The Lancet. Rheumatology|January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialRoy Fleischmann, Alan Friedman, Edit Drescher, et al.
Rheumatology and Therapy|November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid ArthritisPhilip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisStanley Cohen, Sebastião C Radominski, Juan J Gomez-Reino, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitisJeffrey Hyams, Lakshmi Damaraju, Marion Blank, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Annals of the Rheumatic Diseases|June 7, 2017
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence studyStanley Cohen, Mark C Genovese, Ernest Choy, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|April 7, 2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyJürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, et al.
RMD Open|April 19, 2019
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54Rieke Alten, Bogdan Batko, Tomas Hala, et al.
The Lancet. Rheumatology|January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialRoy Fleischmann, Alan Friedman, Edit Drescher, et al.
Rheumatology and Therapy|November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid ArthritisPhilip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisStanley Cohen, Sebastião C Radominski, Juan J Gomez-Reino, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitisJeffrey Hyams, Lakshmi Damaraju, Marion Blank, et al.
Pageof 12